Table 1.

Baseline characteristics of the derivation and validation cohorts.

CHARACTERISTIC	NUMBER OF PATIENTS		% OF PATIENTS		P-VALUE	CHI-SQUARE SCORE
	DERIVATION COHORT	VALIDATION COHORT	DERIVATION COHORT	VALIDATION COHORT
Male sex	193	72	58%	51%	0.158	1.990
Age > 70	148	67	45%	48%	0.549	0.359
Independent ADLs	160	76	48%	54%	0.250	1.323
Not-completely-independent ADLs	128	47	39%	34%	0.285	1.145
PMH CVA	37	15	11%	11%	0.875	0.025
CRI/ESRD	71	29	22%	21%	0.846	0.038
Angina pectoris	102	36	31%	26%	0.258	1.279
CHF (III or IV)	98	36	30%	26%	0.382	0.765
PMH MI	73	24	22%	17%	0.223	1.487
Cancer	82	32	25%	23%	0.645	0.212
Cirrhosis	9	6	3%	4%	0.379	0.773
Dementia	13	4	4%	3%	0.566	0.330
Respiratory insufficiency	114	47	35%	34%	0.839	0.041
Immunocompromised	8	4	2%	3%	0.786	0.074
Sepsis	25	9	8%	6%	0.661	0.193
Pneumonia	46	19	14%	14%	0.916	0.011
Recent MI	90	41	27%	29%	0.656	0.198
CVA	14	8	4%	6%	0.490	0.477
Coma	13	3	4%	2%	0.326	0.965
Ventilation	145	71	44%	51%	0.178	1.817
Hypotension	94	35	28%	25%	0.439	0.599
S3 gallop	1	0	0%	0%	0.514	0.425
Oliguria	4	2	1%	1%	0.848	0.037
Pulmonary edema	73	37	22%	26%	0.313	1.017
Abnl BUN	48	23	15%	16%	0.602	0.272
Abnl Cr	136	51	41%	36%	0.333	0.939
Abnl pH	75	28	23%	20%	0.513	0.427
Abnl PaCO2	95	38	29%	27%	0.717	0.131
Abnl PaO2	23	11	7%	8%	0.734	0.115
Abnl bicarb	31	11	9%	8%	0.593	0.285
Deceased	245	104	74%	74%	0.992	0.000